<p>Nuveen Asset Management LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度其在 Viridian Therapeutics, Inc.（NASDAQ:VRDN - 免费报告）的持股增加了 198.2%。该公司在季度内额外收购了 452,627 股后，持有该公司 681,012 股股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 Viridian Therapeutics 约占 0.86%，价值 13,055,000 美元。</p>
<p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
<p>其他一些大型投资者最近也调整了他们在 VRDN 的持股。R Squared Ltd 在第四季度新购入了 Viridian Therapeutics 的股份，价值约为 26,000 美元。Foresite Capital Management VI LLC 在第四季度新建了约 38,000 美元的 Viridian Therapeutics 持仓。AlphaQuest LLC 在第四季度将其在 Viridian Therapeutics 的持股增加了 119.0%。AlphaQuest LLC 目前持有该公司 2,795 股股票，价值 54,000 美元，此前在上个季度又购买了 1,519 股。Summit Investment Advisors Inc. 在第四季度将其在 Viridian Therapeutics 的持股增加了 24.7%。Summit Investment Advisors Inc. 目前持有该公司 7,646 股股票，价值 147,000 美元，此前在此期间又收购了 1,516 股。最后，Quantbot Technologies LP 在第四季度新购入了约 164,000 美元的 Viridian Therapeutics 持仓。</p>
<h2>Viridian Therapeutics 股票表现</h2>
<p>NASDAQ VRDN 的股票在周二开盘价为 13.57 美元。该股票的 50 日简单移动平均线为 13.13 美元，200 日简单移动平均线为 16.67 美元。该股票的市值为 11.1 亿美元，市盈率为-3.15，贝塔值为 0.57。该公司的速动比率为 18.55，流动比率为 18.55，债务股本比率为 0.04。Viridian Therapeutics, Inc. 的 52 周最低价为 9.90 美元，52 周最高价为 27.20 美元。</p>
<p>Viridian Therapeutics（NASDAQ:VRDN - 获取免费报告）最近在 5 月 6 日（周二）发布了季度财报。该公司报告季度每股收益为（0.87 美元），超出分析师一致预期的（0.95 美元）0.08 美元。该业务在季度内的收入为 0.07 百万美元，而分析师预期为 0.16 百万美元。Viridian Therapeutics 的股本回报率为-70.12%，净利润率为-85,127.16%。该公司季度收入较去年同期增长了 0.0%。整体来看，卖方分析师预测 Viridian Therapeutics, Inc. 本财年的每股收益将为-4.03。</p>
<h2>分析师评级变动</h2>
<p>几位股票研究分析师最近对 VRDN 股票发表了评论。加拿大皇家银行将 Viridian Therapeutics 的目标价从 46.00 美元下调至 45.00 美元，并在 5 月 7 日的报告中给予该股票 “跑赢大盘” 的评级。JMP Securities 将 Viridian Therapeutics 的目标价从 42.00 美元下调至 38.00 美元，并在 5 月 7 日的研究报告中给予该股票 “市场跑赢” 的评级。高盛集团将 Viridian Therapeutics 的目标价从 31.00 美元下调至 27.00 美元，并在 5 月 7 日的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 在 5 月 20 日的报告中重申了 “买入” 评级，并将 Viridian Therapeutics 的目标价设定为 36.00 美元。最后，HC Wainwright 在 4 月 23 日的报告中重新发布了 “买入” 评级，并对 Viridian Therapeutics 的股票设定了 34.00 美元的目标价。一位研究分析师对该股票给予了持有评级，十位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，Viridian Therapeutics 的共识评级为 “适度买入”，共识目标价为 36.70 美元。</p>
<p><strong>查看我们对 VRDN 的最新股票分析</strong></p>
<h2>Viridian Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Viridian Therapeutics, Inc. 是一家生物技术公司，致力于发现和开发针对严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对胰岛素样生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R，并结合半衰期延长技术用于治疗 TED。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Viridian Therapeutics</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>Workday 股票价格暴跌：AI 投资者的自动买入机会</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>MercadoLibre 股价飙升——你应该等待更好的入场时机吗？</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>对市场有疑虑？三只股票可应对恐惧、不确定性和怀疑</li>
</ul>
<p><strong>想看看其他对 VRDN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Viridian Therapeutics, Inc.（NASDAQ:VRDN - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJETg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJETg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Viridian Therapeutics 吗？</h2>
<p>在你考虑投资 Viridian Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 Viridian Therapeutics 并不在名单上。</p>
<p>虽然 Viridian Therapeutics 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VRDN

<p>Nuveen Asset Management LLC 在第四季度将其在 Viridian Therapeutics, Inc. (NASDAQ:VRDN) 的持股增加了 198.2%，目前持有 681,012 股，价值 1305 万美元。其他投资者也调整了他们的持股。VRDN 股票开盘价为 13.57 美元，市值为 11.1 亿美元。该公司报告的季度每股收益为（0.87 美元），超出预期，分析师预测共识评级为 “适度买入”，目标价格为 36.70 美元。Viridian 专注于治疗严重疾病，包括甲状腺眼病</p>

<p>Nuveen Asset Management LLC grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 681,012 shares of the company's stock after acquiring an additional 452,627 shares during the quarter. Nuveen Asset Management LLC owned about 0.86% of Viridian Therapeutics worth $13,055,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Nuveen Asset Management LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度其在 Viridian Therapeutics, Inc.（NASDAQ:VRDN - 免费报告）的持股增加了 198.2%。该公司在季度内额外收购了 452,627 股后，持有该公司 681,012 股股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 Viridian Therapeutics 约占 0.86%，价值 13,055,000 美元。</p>
</div><p>Get <strong>Viridian Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viridian Therapeutics</strong> 的提醒：</p>
</div><p>A number of other large investors also recently modified their holdings of VRDN. R Squared Ltd acquired a new stake in Viridian Therapeutics in the fourth quarter worth about $26,000. Foresite Capital Management VI LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at about $38,000. AlphaQuest LLC raised its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after acquiring an additional 1,516 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Viridian Therapeutics in the fourth quarter valued at approximately $164,000.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也调整了他们在 VRDN 的持股。R Squared Ltd 在第四季度新购入了 Viridian Therapeutics 的股份，价值约为 26,000 美元。Foresite Capital Management VI LLC 在第四季度新建了约 38,000 美元的 Viridian Therapeutics 持仓。AlphaQuest LLC 在第四季度将其在 Viridian Therapeutics 的持股增加了 119.0%。AlphaQuest LLC 目前持有该公司 2,795 股股票，价值 54,000 美元，此前在上个季度又购买了 1,519 股。Summit Investment Advisors Inc. 在第四季度将其在 Viridian Therapeutics 的持股增加了 24.7%。Summit Investment Advisors Inc. 目前持有该公司 7,646 股股票，价值 147,000 美元，此前在此期间又收购了 1,516 股。最后，Quantbot Technologies LP 在第四季度新购入了约 164,000 美元的 Viridian Therapeutics 持仓。</p>
</div><h2>Viridian Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ VRDN opened at $13.57 on Tuesday. The stock's fifty day simple moving average is $13.13 and its 200 day simple moving average is $16.67. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -3.15 and a beta of 0.57. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.</p>
<div class="lb-trans"><p>NASDAQ VRDN 的股票在周二开盘价为 13.57 美元。该股票的 50 日简单移动平均线为 13.13 美元，200 日简单移动平均线为 16.67 美元。该股票的市值为 11.1 亿美元，市盈率为-3.15，贝塔值为 0.57。该公司的速动比率为 18.55，流动比率为 18.55，债务股本比率为 0.04。Viridian Therapeutics, Inc. 的 52 周最低价为 9.90 美元，52 周最高价为 27.20 美元。</p>
</div><p>Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company's revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Viridian Therapeutics（NASDAQ:VRDN - 获取免费报告）最近在 5 月 6 日（周二）发布了季度财报。该公司报告季度每股收益为（0.87 美元），超出分析师一致预期的（0.95 美元）0.08 美元。该业务在季度内的收入为 0.07 百万美元，而分析师预期为 0.16 百万美元。Viridian Therapeutics 的股本回报率为-70.12%，净利润率为-85,127.16%。该公司季度收入较去年同期增长了 0.0%。整体来看，卖方分析师预测 Viridian Therapeutics, Inc. 本财年的每股收益将为-4.03。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities research analysts recently commented on VRDN shares. Royal Bank of Canada dropped their target price on Viridian Therapeutics from $46.00 to $45.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, May 7th. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their target price on Viridian Therapeutics from $31.00 to $27.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 7th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and set a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday, May 20th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, Viridian Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $36.70.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 VRDN 股票发表了评论。加拿大皇家银行将 Viridian Therapeutics 的目标价从 46.00 美元下调至 45.00 美元，并在 5 月 7 日的报告中给予该股票 “跑赢大盘” 的评级。JMP Securities 将 Viridian Therapeutics 的目标价从 42.00 美元下调至 38.00 美元，并在 5 月 7 日的研究报告中给予该股票 “市场跑赢” 的评级。高盛集团将 Viridian Therapeutics 的目标价从 31.00 美元下调至 27.00 美元，并在 5 月 7 日的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 在 5 月 20 日的报告中重申了 “买入” 评级，并将 Viridian Therapeutics 的目标价设定为 36.00 美元。最后，HC Wainwright 在 4 月 23 日的报告中重新发布了 “买入” 评级，并对 Viridian Therapeutics 的股票设定了 34.00 美元的目标价。一位研究分析师对该股票给予了持有评级，十位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，Viridian Therapeutics 的共识评级为 “适度买入”，共识目标价为 36.70 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on VRDN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 VRDN 的最新股票分析</strong></p>
</div><h2>Viridian Therapeutics Profile</h2>
<div class="lb-trans"><h2>Viridian Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.</p>
<div class="lb-trans"><p>Viridian Therapeutics, Inc. 是一家生物技术公司，致力于发现和开发针对严重和罕见疾病的治疗方案。该公司的产品管线包括 VRDN-001，一种针对胰岛素样生长因子-1 受体的单克隆抗体，目前正在进行治疗甲状腺眼病（TED）的三期临床试验；以及 VRDN-003，一种下一代 IGF-1R 人源化单克隆抗体，针对 IGF-1R，并结合半衰期延长技术用于治疗 TED。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Viridian Therapeutics</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Viridian Therapeutics</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>Workday 股票价格暴跌：AI 投资者的自动买入机会</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>MercadoLibre 股价飙升——你应该等待更好的入场时机吗？</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>对市场有疑虑？三只股票可应对恐惧、不确定性和怀疑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRDN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 VRDN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Viridian Therapeutics, Inc.（NASDAQ:VRDN - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJETg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRDN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viridian Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Viridian Therapeutics 吗？</h2>
</div><p>Before you consider Viridian Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Viridian Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 Viridian Therapeutics 并不在名单上。</p>
</div><p>While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viridian Therapeutics 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nuveen Asset Management LLC 增加了其对 Viridian Therapeutics, Inc.（NASDAQ:VRDN）的股票持仓